Company Leadership

Meg Powell, Pharm.D.
CEO, President, and Co-Founder

Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. Currently she is serving as CEO of TARGET PharmaSolutions.

She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies.  These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.

Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.

Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar.  She also received a Master’s of Business Administration from Stanford University.

George Demuth
Vice President, Data Management And Statistical Reporting

Mr. DeMuth has over 25 years of experience working as a lead statistician on clinical trials in support of pharmaceutical, medical device, and biologic products. He previously owned and operated a clinical research organization (CRO) for 17 years. Mr. DeMuth has worked with several hundred companies across numerous therapeutic areas and supported many approved products. He has attended numerous FDA meetings as the client’s representative and has presented at FDA panel meetings. Mr. DeMuth has extensive programming experience and has developed several statistical reporting packages using SAS macros. He has also developed Stat One EDM TM, an electronic data capture system.

Weston Fox
Vice President, Corporate Development

Weston is currently serving as Vice President, Corporate Development for TARGET PharmaSolutions.

Prior to joining TARGET, Weston was a Director at Novartis in their Global Development organization.  Prior to Novartis, Weston worked for a number of years at Quintiles in a variety of positions, including Corporate Development, Business Development and Operations.  His most recent position at Quintiles was Executive Director, Global Sales where he was responsible for Quintiles’ global Business Development activities for two enterprise accounts.  Weston also previously worked for The Boston Consulting Group and Carousel Capital, a mid-market focused private equity firm.

Weston received his MBA from the Kenan-Flagler Business School at the University of North Carolina and his BA from the University of Virginia where he was a Jefferson Scholar.

Melissa Mulauski
Director of Human Resources

 

Melissa is currently serving as Director of Human Resources at TARGET PharmaSolutions. Melissa Mulauski has over 18 years of human resources experience in employee relations, training, policy development, compensation, and recruiting.

Melissa spent 6 years working at Quintiles in their Human Resources department and another 3 years heading the Human Resources department at Peopleclick before joining Strategic HR Solutions as a Consultant.

Melissa is professionally certified as a Senior Professional in Human Resources (SPHR) and also as a SHRM Senior Certified Professional (SCP). She holds a Bachelor of Science degree in Labor and Industrial Relations with a Business minor from The Pennsylvania State University.

 

Judy Atkins
Vice President of Quality and Compliance

Judy Atkins is currently serving as Vice President of Quality and Compliance at TARGET PharmaSolutions. 

Judy Atkins received her BS,MS, Doctorate of Pharmacy, and Pharmacy degree from the University of North Carolina- Chapel Hill.  

Jason Fox
Vice President of Technology

 

Jason Fox is currently serving as Vice President of Technology at TARGET PharmaSolutions.

Jason has over 15 years’ experience in software engineering and architecture, including stints at NASA’s Jet Propulsion Laboratory and SAS. Jason is an expert in building high performing, highly available software systems for a wide array of industries. Whether it is mission support software for robotic exploration of Mars, or scalable frameworks for high-end analytics, Jason brings his methodical approach and deep understanding of computer systems to solving difficult problems.

Jason received his Master’s degree in Computer Science from Purdue University and his Bachelors in Computer Science Engineering from The Ohio State University.

 

Michael W. Fried, MD
Scientific Advisor and Co-Founder

Michael W. Fried, MD is Professor of Medicine and Director of Hepatology at the University of North Carolina at Chapel Hill.  Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.

From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis.  During his tenure at UNC, he has been the principal investigator on numerous phase I, II, and III clinical trials of antiviral agents for chronic hepatitis B and hepatitis C.  Dr. Fried has been awarded continuous NIH extramural funding for more than 15 years as principal investigator on multiple NIH cooperative clinical trials, including as current co-Chair of the Hepatitis B Research Network (NIDDK).

Dr. Fried is the recipient of an NIH career development award, which allows him to provide mentorship to junior investigators in hepatitis research.  Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network of investigators to study the real-world experience with therapies for hepatitis C.

Dr. Fried is the primary author or co-author on over 140 original publications, reviews, and book chapters concentrated in the field of viral hepatitis.  His manuscript on therapy of HCV, published in 2002, established the standard of care for this disease for more than a decade and was one of the most highly cited publications in the field of gastroenterology.

Dr. Fried was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.  Dr. Fried was recently elected to the Governing Board of the American Association for the Study of Liver Diseases (AASLD) and will assume the role of President of AASLD in 2019.

Jennifer Woods
Controller

Jen Woods is currently serving as Controller for TARGET PharmaSolutions.

Jen Woods has over 15 years of experience in the accounting and finance industry serving a variety of sectors, including life sciences, telecommunications, and banking. Before joining TARGET, Jen held various positions at Ernst & Young, LLP, the American Institute of CPAs, and Wachovia Bank. Most recently, she served in accounting and finance roles for private companies and non-profits. Jen is a client-focused, team player with strong communication skills and a proven track record of managing assignments and directing teams of professionals to produce results.

Jeffrey K. Giguere, MD
Board Observer

Dr. Giguere is currently a practicing Oncologist and Principal Investigator at Greenville Health Systems Cancer Institute in Greenville, South Carolina. He has held the position of Principal Investigator since 1995 where he has overseen its dramatic expansion. Additionally Dr. Giguere has served as President of the South Carolina Oncology Society. He has received various awards for his work including honors from the American Board of Internal Medicine, the National Board of Medical Examiners and the prestigious Gen. Graves Ersike Award for Outstanding Fellow at Walter Reed Army Medical Center.

He is also active in the Greenville, SC community where he sits on the board of a philanthropy committee of a $4.8 million park dedicated to Cancer Survivors.

Dr. Giguere holds a BS and MD from Duke University and completed his residency at Vanderbilt University. He also served in the United State Air Force as a practicing physician at both USAF Hospital in Plattsburgh, NY and at Walter Reed Army Medical Center in Washington, DC.

Bobby Helmedag
Board Member

Bobby manages the operations of Rex Health Ventures, a corporate venture fund backed by UNC Rex Healthcare in Raleigh, NC.  Since its launch in 2012, Rex Health Ventures has invested in 8 portfolio companies across several areas of healthcare including medical devices, healthcare services, diagnostics, technology enabled services and drug development.  Bobby is responsible for deal sourcing, due diligence and portfolio management.

Prior to Rex Health Ventures he worked at Blue Cross Blue Shield of Tennessee in corporate development.

He has an International MBA from the University of South Carolina and a Bachelor’s of Finance from the University of Notre Dame.

Moise A. Khayrallah, PhD
Board Member

Dr. Khayrallah has been involved in drug development for over 28 years in executive as well as research and development positions having acquired his experience in diverse pharmaceutical environments including large pharmaceutical, contract research, and biotechnology companies. Currently he is Chairman of the Board and co-Founder of QuatroBio, LLC, a biopharmaceutical holding company focused on developing drugs for central nervous system disorders. He has extensive experience in the entrepreneurial space having lead multiple healthcare companies including Aerial Biopharma, Neruronex Inc, and Addrenex Pharmaceuticals.

Additionally Dr. Khayrallah is actively involved in philanthropic, entrepreneurial and social networks in North Carolina. In 2014 he endowed the Moise A. Khayrallah Center for Lebanese Diaspora Studies at North Carolina State University, the first center of its kind outside of Lebanon. The Center is the first endowed center in NC State’s history and the largest gift to the College of Humanities and Social Sciences. He is also Chairman of the Board of the UNC Center for International Understanding where he works with the Center on enhancing North Carolina’s global engagement. Additionally Dr. Khayrallah is highly involved in the North Carolina Ballet at his position of Chairman of the Board.

Dr. Khayrallah holds a Ph.D. degree in Psychology from the University of North Carolina at Chapel Hill and a Bachelor’s degree in Psychology from the American University of Beirut.

Meg Powell, Pharm.D.
CEO, President, and Co-Founder

Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. Currently she is serving as CEO of TARGET PharmaSolutions.

She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies.  These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.

Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.

Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar.  She also received a Master’s of Business Administration from Stanford University.